P.261Consistent long-term effect of idebenone in reducing respiratory function decline in advanced patients with Duchenne muscular dystrophy

2019 ◽  
Vol 29 ◽  
pp. S143
Author(s):  
G. Buyse ◽  
L. Servais ◽  
O. Mayer ◽  
C. McDonald ◽  
T. Voit ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Respiratory Function ◽  
Term Effect ◽  
Long Term Effect

scholarly journals Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy

2020 ◽  
Vol 30 (1) ◽  
pp. 5-16 ◽  
Author(s):  
Laurent Servais ◽  
Chiara S.M. Straathof ◽  
Ulrike Schara ◽  
Andrea Klein ◽  
Mika Leinonen ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Respiratory Function ◽  
Term Data

scholarly journals Idebenone as a Novel Therapeutic Approach for Duchenne Muscular Dystrophy

2015 ◽  
Vol 10 (2) ◽  
pp. 189 ◽  
Author(s):  
Gunnar M Buyse ◽  
Nuri Gueven ◽  
Craig M McDonald ◽  
◽  
◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Respiratory Function ◽  
Morbidity And Mortality ◽  
Phase Iii ◽  
Atp Production ◽  
Airway Clearance ◽  
Dystrophin Deficiency ◽  
Confirmatory Phase

Progressive loss of pulmonary function leads to early morbidity and mortality in Duchenne muscular dystrophy (DMD) due to both expiratory impairment with ineffective airway clearance, and inspiratory impairment leading to nocturnal and daytime hypoventilation and respiratory failure. Glucocorticoid steroids have become a mainstay of DMD therapy with well-documented efficacy on muscle strength and respiratory function. However, the side-effect profile restricts their long-term use, particularly in non-ambulant patients. Idebenone improves secondary mitochondrial dysfunction caused by dystrophin deficiency, intracellular calcium accumulation and increased reactive oxygen species (ROS). Idebenone-mediated improved bioenergetics leads to enhanced adenosine triphosphate (ATP) production and reduced ROS. Based on this rationale, idebenone has been investigated clinically for efficacy on reducing respiratory function decline in exploratory phase II (DELPHI) and confirmatory phase III (DELOS) trials. Idebenone significantly reduced the loss of respiratory function in 8–18-year-old DMD patients who were not using concomitant glucocorticoids. These results indicate that idebenone can modify the natural course of respiratory disease progression in DMD, which is relevant in clinical practice where loss of respiratory function continues to be a predominant cause of early morbidity and mortality in DMD.

Long-term effect of bariatric surgery on respiratory function in severe uncomplicated obesity

Therapy ◽  
2007 ◽  
Vol 4 (5) ◽  
pp. 555-559
Author(s):  
Mauro Maniscalco ◽  
Anna Zedda ◽  
Stanislao Faraone ◽  
Maria Rosaria Cerbone ◽  
Valentina Antognozzi ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Respiratory Function ◽  
Term Effect ◽  
Long Term Effect

P.264SYROS study – long-term reduction in rate of respiratory function decline in patients with Duchenne muscular dystrophy treated with idebenone

2019 ◽  
Vol 29 ◽  
pp. S144
Author(s):  
L. Servais ◽  
O. Mayer ◽  
C. McDonald ◽  
C. Straathof ◽  
U. Schara ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Respiratory Function

A long-term effect of subliminally presented words

2010 ◽  
Author(s):  
Andreas T. Breuer ◽  
Michael E. J. Masson ◽  
Glen E. Bodner
Keyword(s):  
Term Effect ◽  
Long Term Effect
Sign in / Sign up

Export Citation Format

Share Document